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ABSTRACT
Background: Atherosclerosis is the major cause of  morbidities 
and mortalities worldwide. In this study we aimed to review 
the mechanism of  atherosclerosis and its risk factors, focusing 
on new findings in atherosclerosis markers and its risk factors. 
Furthermore, the role of  antioxidants and medicinal herbs in 
atherosclerosis and endothelial damage has been discussed and 
a list of  important medicinal plants effective in the treatment and 
prevention of  hyperlipidemia and atherosclerosis is presented.
Methods: The recently published papers about atherosclerosis 
pathogenesis and herbal medicines effective in the treatment and 
prevention of  hyperlipidemia and atherosclerosis were searched.
Results: Inflammation has a crucial role in pathogenesis 
of  atherosclerosis. The disease is accompanied by excessive 
fibrosis of  the intima, fatty plaques formation, proliferation of  
smooth muscle cells, and migration of  a group of  cells such as 
monocytes, T cells, and platelets which are formed in response 
to inflammation. The oxidation of  low density lipoprotein (LDL) 
to Ox‑LDL indicates the first step of  atherosclerosis in 
cardiovascular diseases. Malondialdehyde factor shows the level of  
lipoperoxidation and is a sign of  increased oxidative pressure and 
cardiovascular diseases. In special pathological conditions such as 
severe hypercholesterolemia, peroxynitrite concentration increases 
and atherosclerosis and vascular damage are intensified. Medicinal 
plants have shown to be capable of  interacting these or other 
pathogenesis factors to prevent atherosclerosis.
Conclusions: The pathogenesis factors involved in atherosclerosis 
have recently been cleared and the discovery of  these factors has 
brought about new hopes for better prevention and treatment of  
atherosclerosis.
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INTRODUCTION
Atherosclerosis is the result of  hyperlipidemia and lipid 
oxidation and has always been a major cause of  mortality 
in developed countries. It is a disease of  vascular intima, in 
which all the vascular system from aorta to coronary arteries 
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can be involved and is characterized by intimal 
plaques.[1,2]
The term atherosclerosis is of  Greek origin, 
meaning thickening of  the intimal layer of  arteries 
and accumulation of  fat. Fatty material is located 
in the central core of  the plaque, covered by fibrous 
cap. The term, atherosclerosis consists of  two parts; 
atherosis (accumulation of  fat accompanied by 
several macrophages) and sclerosis (fibrosis layer 
comprising smooth muscle cells [SMC], leukocyte, 
and connective tissue).[3,4]
Currently, atherosclerosis is a common disease 
in which fatty deposits called atheromatous plaques 
appear in the inner layers of  arteries. Formation of  
these plaques starts with the deposition of  small 
cholesterol crystals in the intima and its underlying 
smooth muscle. Then the plaques grow with the 
proliferation of  fibrous tissues and the surrounding 
smooth muscle and bulge inside the arteries and 
consequently reduce the blood flow. Connective 
tissue production by fibroblasts and deposition of  
calcium in the lesion cause sclerosis or hardening 
of  the arteries. Finally, the uneven surface of  the 
arteries results in clot formation and thrombosis, 
which leads to the sudden obstruction of  blood 
flow.[5]
Hyperlipidemia and hyperglycemia are related 
to increased oxidative damage, which affects 
antioxidant status and lipoprotein levels.[6‑8] Studies 
have shown that lipid lowering medicinal herbs can 
reduce the blood lipids especially after meals in 
addition to their antioxidant effects. Therefore, 
they can prevent atherosclerosis and vascular 
endothelium damage.[6]
There are a couple of  valuable review papers 
addressing the pathogenesis of  atherosclerosis.[7,8] 
In this study, we aimed to review the mechanism 
of  atherosclerosis and its risk factors, focusing on 
new findings in atherosclerosis markers and its risk 
factors. Furthermore, the role of  antioxidants and 
medicinal herbs in atherosclerosis and endothelial 
damage has been discussed and a list of  important 
medicinal plants effective in the treatment and 
prevention of  hyperlipidemia and atherosclerosis 
is presented.
METHODS
The recently published papers about 
atherosclerosis pathogenesis and herbal medicines 
effective in the treatment and prevention 
of  hyperlipidemia and atherosclerosis were 
searched in databases such as Web of  Science, 
Medline, PubMed, Scopus, Embase, Cinhal 
and the Cochrane from 2000 to 2013. The 
keywords searched included hyperlipidemia, 
Atherosclerosis, Pathogenesis of  atherosclerosis, 
Atherosclerosis risk factors and biomarkers, 
Medicinal plants and atherosclerosis as well as 
herbal medicine and atherosclerosis.
RESULTS
The atherosclerosis process
•	 Fatty	streaks	formation
•	 Atheroma	formation
•	 Atherosclerotic	plaques	formation.
Fatty streaks formation
Both animal and human studies show that the 
fatty streaks are the first sign of  atherosclerosis. 
The initial lesions are usually caused by the focal 
increase in the lipoproteins of  the intimal layer of  
the arteries.[5]
Lipoprotein particles are composed of  proteins, 
phospholipids, and also lipids such as cholesterol 
and triglyceride. One of  the most important 
atherogenic lipoproteins is the cholesterol‑rich low 
density lipoprotein (LDL). This lipoprotein can be 
accumulated in the vascular intima due to its ability 
to infiltrate into the endothelium or to adhere to 
extracellular matrix components like proteoglycan.
At the site of  lesions, the balance between 
the different components of  the matrix may be 
disturbed. For instance, among the three main 
groups of  proteoglycans, the relative increase in 
heparin sulfate molecules in comparison with 
keratan sulfate and chondroitin sulfate may cause 
the adhesion of  lipoproteins, which slows down 
the process of  exiting from the intima leading to 
their accelerated accumulation.[9]
In the initial steps of  atheroma formation, 
plaques usually grow through the opposite 
direction of  the vessel. Atherosclerotic vessels 
are willing to grow in diameter. When a plaque 
covers more than 40% of  internal elastic layer of  
the vessel, the arterial channel is considered to be 
occupied. At the end of  the plaque’s lifetime, the 
restrictive obstruction of  the blood flow happens. 
Studies show that atherosclerosis is a result of  
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Low density lipoprotein trapping results in the 
increased concentration of  LDL in the intima as 
well as increased duration of  their stay in the lesion. 
Both such factors lead to spontaneous oxidation 
and cell oxidation of  the trapped particles.[5]
Activation of endothelial cells
Cytokines and oxidized lipids play important 
roles in the activation of  endothelial cells. During 
the early steps of  atherosclerosis, monocytes and 
T lymphocytes infiltrate into vascular intima.[11]
Meanwhile the produced adhesion and 
absorbing molecules are important because of  
various molecular types during LDL oxidation.[12] 
Monocyte‑to‑macrophage differentiation causes 
them to take oxidized lipids such as oxidized 
LDL (Ox‑LDL) to form foam cells.[13] This process 
depends on the expression of  receptors for cleaning 
the secretions of  enzymes and different cytokines. 
Ox‑LDL plays a role in the activation of  T cells and 
works as an antigen for T cells; hence, secreting 
cytokines to activate the macrophages and alter the 
endothelial and SMC.[11]
Leukocytes activation
During the initial steps of  atherosclerosis, 
mononuclear leukocytes, monocytes, and T cells 
enter the intact endothelium through vascular walls. 
This process needs the expression of  leukocyte 
and chemokine adhesion molecules in which 
the transcription is performed by NF‑αβ factor. 
This factor is a transcription factor and becomes 
intima damage with some cellular responses that 
involve monocytes, SMC, and lymphocytes. The 
initial soft lesion is composed of  foam cells and 
extracellular fat deposits and a small number of  
platelets. During the progress of  the process, SMC 
proliferate and in the final steps, intensify bleeding 
into the plaque[5‑10] [Figure 1].
The formation of fatty streaks has four steps
•	 Low	 density	 lipoprotein‑cholesterol	 (LDL‑C)	
trapping
•	 Activation	of 	endothelial	cells
•	 Leukocytes	activation
•	 Formation	of 	foam	cells.
Low density lipoprotein‑cholesterol trapping
The first step in atherogenesis is trapping the 
lipoprotein in the lesion site. Although, LDL‑C 
cannot pass through the firm endothelial junctions, 
it can rapidly enter the endothelial cells through 
endocytosis.
In normal conditions, there is equilibrium 
between the plasma LDL and intracellular LDL 
concentration of  arterial walls. Along with an 
increase in plasma lipids many of  these particles 
become trapped in the intima (because of  the 
increased extracellular proteoglycans, which have a 
high LDL affinity).[5] Because of  the direct correlation 
between serum LDL concentration and the amount 
of  lipoprotein trapping in the lesion, its blood level 
can be considered as an indicator of  atherogenesis.
Figure 1: Sages of fatty streaks formation
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activated when pro‑inflammatory cytokines bind 
to their receptors on the endothelial surface.
Leukocyte adhesion molecules are involved in 
the primary stages of  atherosclerosis. Endothelial 
cells are important sources for producing adhesion 
molecules on leukocytes.
Receptors of  adhesion molecules express on the 
specific leukocytes, SMC, or vascular endothelial 
cells. It has been shown that adhesion molecules 
have an important role in production and release 
of  attractant molecules and/or chemokines. 
Chemokines are proteins or attractant cytokines with 
a low molecular weight (8‑10 kDa), which have a 
pivotal role in leukocytes activation and migration.[14]
Moreover, specific chemokines cause endothelial 
and SMC to migrate. Studies have demonstrated 
that in the first steps of  atherosclerosis, inhibitory 
monocyte chemokine protein (MCP‑1) is expressed 
considerably by macrophages and in a less amount 
by SMC and endothelium. This enhancement is 
resulted from the increased dietary cholesterol and 
causes monocytes to move toward the vascular 
walls and infiltrates them into the lesion. MCP‑1 is 
expressed in all steps of  atherosclerosis.[15]
It has currently been shown that Ox‑LDL 
up regulates the adhesion molecules. It also 
expresses messenger ribonucleic acid (mRNA) 
MCP in the endothelial and SMC by means of  
lysophosphatidylcholine which is resulted from A2 
phospholipase function on LDL.[16]
Foam cell formation
Mononuclear phagocytes differentiate to 
macrophage after insertion in the intima. Phagocytes 
may participate in preventing atherosclerosis by 
phagocytosis of  lipids from the extracellular space. 
Some lipid accumulated macrophages may leave the 
arterial wall and take out the lipids from the artery. If  
the level of  lipid entrance into the artery wall is more 
than its exiting (by phagocytes or other ways), it will 
lead to accumulation of  lipids and consequently the 
tendency to form atheroma is increased.
Macrophages perform uptake and accumulation 
of  Ox‑LDL by their scavenger receptors, which will 
be converted to foam cells.[17] The expression of  these 
receptors on the surface of  macrophages, endothelial 
cells, fibroblasts, and SMC has been documented.[18]
Expression of  these scavenger receptors 
increase during differentiation of  monocytes to 
macrophages by cytokines and oxidized lipids. 
Their expression is also facilitated by macrophage 
colony‑stimulating factor.[17]
The surface Ox‑LDL ligand that causes its 
absorption to scavenger receptors of  macrophages, 
are phospholipids in the structure of  Ox‑LDL, 
which will be oxidized in location two, and form 
aldehydes which are able to attack lysine residues 
of  ApoB.[18,19] Accumulation of  these yellow foam 
cells on the arterial walls lead to the formation of  
lipid streaks.[20]
Some foam cells in the developing intimal lesion 
die through apoptosis. This apoptosis makes a 
lipid rich necrosing nucleus in the center of more 
developed atherosclerotic plaque. Monocytes, other 
than producing foam cells, can produce cytotoxic 
substances such as tumor necrosis factor (TNF), 
growth factor, precoagulation substances (including 
tissue factors), and free radicals. These substances can 
cause more damage to endothelium as well as more 
LDL oxidation, leading to more metabolic changes.[20]
Atheroma formation
Severe damage to vascular tissue happens when 
adjacent SMC and endothelial cells secret small 
peptides such as cytokines and growth factors such 
as interleukin 1 (IL‑1), and TNF (which causes cell 
growth). These factors cause SMC to migrate into the 
luminal side of  vessel wall. In this condition, smooth 
muscle cell migration and synthesized extracellular 
matrix form the fibrous cap. Fibrous cap is composed 
of  collagen‑rich fiber tissues, SMC, macrophages 
and T lymphocytes. All of  them form the mature 
atherosclerosis plaque and bulge into the channel and 
reduce the blood stream in the vessels.[17]
Macrophages and T lymphocytes are found in 
the borders of  developed plaque. Macrophages 
secrete meta proteinase, which contribute to 
the lysis of  extracellular matrix. T cells produce 
TNF‑α which prevents the collagen synthesis in 
the SMC.
These processes weaken the formed plaque 
shaped fibrous cap and can destroy it. Destruction 
of  fibrous cap exposes collagen and lipids to blood 
stream which contributes to accumulation and 
adhesion of  platelets and blood clot formation 
which may suddenly block the blood stream[17‑20] 
[Figure 2].
Atherosclerotic plaque formation
Atherosclerotic plaques constituents are as 
follows:
•	 Vascular	epithelium:	Vascular	epithelium	reacts	
with macromolecules and blood components 
to increase the protein transfer in plasma
•	 Arterial	 smooth	 muscle:	 The	 maintenance	
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of  vascular repair and metabolism of  blood 
products including lipids, and the secretion of  
various cytokines, is essential in the control of  
vascular wall tonus
•	 Lymphocytes:	 They	 may	 participate	 in	 the	
immune reactions. The core of  plaque is 
composed of  cell lesions, foam cells, calcium, 
cholesterol esters, and a mass of  fatty substances. 
Lipid nucleus is a pale yellow mass, which 
its color is caused by carotenoid pigments[2] 
[Figure 3].
Atherosclerosis risk factors and indicators
The exact causes and risk factors of  
atherosclerosis are unknown; however, certain 
conditions, traits, or habits may raise the chance 
of  developing atherosclerosis [Table 1]. Most risk 
factors including high cholesterol and LDL, low 
level of  high density lipoprotein (HDL) in the blood, 
hypertension, tobacco smoke, diabetes mellitus, 
obesity, inactive lifestyle, age can be controlled and 
atherosclerosis can be delayed or prevented.[7,8,19]
Cholesterol increase
Cholesterol is a hydrophilic lipid that 
is progenitor of  steroid hormones such as 
corticosteroids, sex hormones, bile acids, and 
vitamin D. Cholesterol is a major component of  
cell membrane. It has two synthetic and dietary 
sources. Half  of  the body’s cholesterol is provided 
by synthesis, mainly in the liver of  mammals while 
all tissues containing nucleated cells are able to 
synthesize cholesterol.[20‑22]
Cholesterol exists in everyone’s diet. It can 
slowly be absorbed into intestine lymphatic 
vessels through gastrointestinal (GI) tract. The 
cholesterol which exists in GI tract is slightly fat 
soluble and can form esters after reaction with 
fatty acids. In fact 70% of  plasma cholesterol is 
in the form of  ester cholesterol. Cholesterol is 
only found in animals. Egg yolk and animal fat 
contain the maximum amount of  cholesterol. 
Cholesterol is absorbed in intestine and enters 
the blood as chylomicrons through the mucosa 
of  digestive system. Cholesterol is synthesized 
inside the cell and the excess amounts are inhibited 
by 3‑hydroxy‑3‑methylglutaryl‑CoA reductase. 
Esterification increases cholesterol synthesis and 
decrease LDL receptors synthesis. All these steps 
regulate the amount of  intracellular cholesterol 
through feedback control.[23]
Extracted cholesterol from cells can be 
absorbed by HDL. Some types of  HDL contain 
apoprotein E and bind to other cells along with 
LDL receptors. They transfer cholesterol from one 
cell to another. Chylomicrons in intestinal mucosa 
enter the blood stream through lymphatic vessels 
along with absorption of  fat digested products. 
Chylomicrons decompose to free fatty acids and 
glycerol in capillaries by lipase protein function and 
undergo esterification after entering into fat cells. 
Chylomicrons contain apoprotein C and remain 
as chylomicron residue called rich lipoprotein 
after triglyceride depletion. These residues will be 
transferred to the liver, bind to their receptors and 
LDL	and	then	enter	cells	rapidly.	Very	low	density	
lipoprotein	 (VLDL)	 is	also	made	 in	 the	 liver	and	
transfer triglycerides, which are formed from lipids 
and carbohydrates in liver, to extra‑hepatic tissues. 
Subsequently,	triglycerides	separate	from	VLDL	by	
lipoprotein lipase and will be converted to LDL. 
Binding HDL to specific superficial parts, which 
function as LDL receptors, is another mechanism 
Figure 2: Atheroma formation
Figure 3: Atherosclerotic plaque formation
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that causes cholesterol to exit by HDL. This 
binding transfers the intracellular cholesterol to 
plasma membrane. Cholesterol turns into LDL 
after esterification.[24]
Familial hypercholesterolemia is a heritable 
disease in which defected genes for LDL receptors 
formation on the surface of  cells are inherited. 
Liver is not able to absorb LDL in the absence 
Table 1: The risk factors of atherosclerosis
Category No. Risk Comments
Major 1 Unhealthy blood cholesterol 
and lipoproteins levels
Broadly, the ideal levels for cholesterol and 
various lipoproteins are as follows
Total cholesterol ≤5mmol/L
Cholesterol: HDL ratio ≤4
LDL cholesterol ≤3mmol/L
HDL cholesterol ≥1mmol/L
2 High blood pressure Blood pressure is considered high if it stays at or above 140/90 mmHg 
over time. If you have diabetes or chronic kidney disease, high 
blood pressure is defined as 130/80 mmHg or higher
3 Smoking Smoking doesn’t allow enough oxygen to reach the body’s 
tissues. Smoking can also damage and tighten blood vessels, 
raise cholesterol levels, and raise blood pressure
4 Insulin resistance This condition occurs if the body can’t use its insulin 
properly. Insulin resistance may lead to diabetes
5 Diabetes The body doesn’t make enough insulin or doesn’t use 
its insulin properly, hence the blood sugar is high
6 Overweight or obesity The terms “overweight” and “obesity” refer to body weight that’s 
greater than what is considered healthy for a certain height
7 Lack of physical activity A lack of physical activity can worsen other risk factors for 
atherosclerosis, such as unhealthy blood cholesterol levels, 
high blood pressure, diabetes and overweight and obesity
8 Unhealthy diet Foods that are high in saturated and trans fats, cholesterol, sodium 
and sugar can worsen other atherosclerosis risk factors
9 Older age Genetic or lifestyle factors cause plaque to build up in the 
arteries as with age. In men, the risk increases after age 
45 and in women, the risk increases after age 55
10 Family history of 
early heart disease
Your risk for atherosclerosis increases if your father or a brother was 
diagnosed with heart disease before 55 years of age, or if your mother 
or a sister was diagnosed with heart disease before 65 years of age
11 Inflammation Inflammation is the body’s response to injury or infection. Damage to the 
arteries inner walls seems to trigger inflammation and help plaque grow
Emerging 
risk 
factors*
12 High levels of CRP High levels of CRP are a sign of inflammation in the body and 
high level of CRP may develop atherosclerosis at a higher rate. 
Research is under way to find out whether reducing inflammation and 
lowering CRP levels also can reduce the risk for atherosclerosis
13 Triglycerides High levels of triglycerides in the blood also may raise 
the risk for atherosclerosis, especially in women
14 Sleep apnea Untreated sleep apnea can raise the risk for high blood 
diabetes, pressure and even a heart attack or stroke
15 Stress The most commonly reported “trigger” for a heart attack is an 
emotionally upsetting event, especially the one involving anger
16 Alcohol Heavy drinking can damage the heart muscle and worsen other risk 
factors for atherosclerosis
*Several other possible risk factors have been Scientists continue to study other for atherosclerosis. CRP=C‑reactive protein, 
HDL=High density lipoprotein, LDL=Low density lipoprotein
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of  these receptors. Without the natural return 
of  cholesterol to the hepatic cells, cholesterol 
production of  hepatic cells is activated and the new 
cholesterol is formed and the feedback inhibition 
of  high cholesterol levels is no longer responding. 
Consequently,	 the	 liver	 transfer	 of 	 VLDL	 to	 the	
plasma will be highly increased.[25]
Hypercholesterolemia increases superoxide free 
radicals production in the vessels and decreases 
synthesis and release of  endothelium derived 
vasodilators. It also increases nitric oxide (NO) 
deactivation after its release from endothelial cells.[3,17]
Apolipoproteins and lipoproteins
High concentrations of  some plasma lipoproteins 
are related to atherogenesis. Atheromagen lipoproteins 
include	 VLDL,	 LDL,	 and	 intermediate‑density	
lipoproteins. Cholesterol esters are found in atheroma 
cells and in the extracellular matrix. They can induce 
fibroblasts to produce collagen.
Cholesterol levels show total cholesterol 
including ester cholesterol and unesterified 
cholesterol. Triglyceride and cholesterol levels 
give some information about serum lipoproteins. 
Elevated plasma cholesterol level shows that 
concentration	of 	 chylomicron	or	VLDL	and	also	
LDL	 have	 increased.	 Increased	 plasma	 VLDL	
concentration and decreased HDL cholesterol are 
seen in people with small but high density LDL 
particles. Four cell types including endothelial cells, 
SMC, macrophages, and lymphocytes are able to 
oxidize LDL. Since unsaturated fatty acids which 
are located on side‑chains of  ester cholesterol and 
LDL’s phospholipids are main substrates for LDL 
lipid oxidation, their amount indicates the LDL 
oxidation capability.[26]
There are six main categories and various 
sub‑categories for apolipoproteins. Apolipoproteins B 
or ApoB is responsible in forming LDL, which is also 
known as bad cholesterol. Most of  these proteins’ 
structure is beta‑sheet, which irreversibly associate 
with lipid droplets. Good cholesterol or HDL is 
another form of  apolipoproteins that are composed 
of  alpha‑helices. Unlike the LDL, HDL reversibly 
associates with lipid droplets. Three‑dimensional 
structure of  these proteins is changed while binding 
to lipids.[27]
Apolipoprotein A‑1 (ApoA) is a hydrophilic 
glycoprotein, which resembles plasminogen 
(a plasmin proenzyme that solves fibrin fiber). 
It can inhibit fibrinolysis in competition with 
plasminogen.[28]
Apolipoprotein A‑1 is the main protein in HDL, 
which constitutes about 70‑80% of  HDL’s protein 
weight. ApoA‑I can be synthesized both in liver 
and in small intestine and functions as an activator 
for lecithin cholesterol acetyl transferase (LCAT) 
enzyme which esterifies the free plasma cholesterol. 
ApoA‑II is the second apoprotein in HDL particles 
which can be synthesized both in liver and small 
intestine and may have an activating role for LCAT 
enzyme.[29]
ApoB is a main transporter to carry cholesterol 
to various body compartments. Its function is 
being a ligand for LDL receptors. High levels of  
ApoB may form plaques leading to atherosclerosis 
and finally to heart disease, mechanism of  which 
is not thoroughly understood. It has been shown 
that plasma ApoB levels indicate the risk of  heart 
disease more accurately compared with serum 
LDL or total cholesterol levels, although assessing 
serum total and LDL cholesterol is still the primary 
test for determining the risk of  atherosclerosis.[27]
Recently, there has been a challenge about 
the concept that increased HDL cholesterol 
concentrations will result in improved 
cardiovascular risk. However, Onat et al. indicated 
that high HDL cholesterol concentrations do not 
usually protect against future risk of  coronary 
heart disease or diabetes.[30,31]
Along with providing ample evidence that high 
concentrations of  serum ApoA‑1 can also lose 
antioxidant and atheroprotective functions relative 
to cardiometabolic risk, Onat and Hergenç, 
developed the concept of  dysfunction of  ApoA‑1 
and HDL particles in a milieu of  enhanced 
low‑grade inflammation in the population.[32] They 
also in a large systematic review of  randomized 
trials[33] disclosed a lack of  association between 
treatment‑induced change in HDL cholesterol and 
risk ratios for cardiovascular disease morbidity and 
mortality, when changes in LDL cholesterol were 
adjusted. Evidence is further beginning to emerge 
that the antioxidant and atheroprotective functions 
of  ApoA‑1, become impaired in the process of  
autoimmune activation. Such impairment could 
be linked to excess circulating lipoprotein(a) and 
its oxidized phospholipids, and could represent a 
common denominator underlying various different 
chronic diseases.[32‑34]
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Thus, it is time to recognize that the clinical 
significance of  HDL cholesterol concentrations in 
the general population is markedly heterogeneous, 
and high concentrations do not necessarily 
imply reduced cardiometabolic risk. Evidence is 
presented that enhanced systemic inflammation, 
or oxidative stress associated with elevated plasma 
triglyceride rich lipoproteins and their remnants, 
and excess oxidized lipoA phospholipids underlie 
this risk. The adverse risk profile is augmented 
by loss of  the anti‑inflammatory, antioxidative 
and atheroprotective properties of  HDL and its 
apoprotein. Common clinical manifestations are 
atherogenic dyslipidemia and hypertriglyceridia 
with elevated ApoB or hypertriglyceridemic 
waste phonotype. Those manifestations are 
accompanied by such inflammatory mediators/
markers as elevated ApoB, C‑reactive protein 
(CRP), complement C3 and uric acid levels. Much 
research is needed on this topic to further clarify 
the impact of  ApoA‑1 dysfunction to elucidate 
the underlying genetics and mechanisms and 
to determine preventive measures and optimal 
managements.[32‑35]
Lipid oxidation
During oxidation, LDL converts to Ox‑LDL. 
Ox‑LDL activates T cells and macrophages, 
stimulates the expression of  adhesion molecules, 
attracts macrophages to sarcoplasmic reticulum, 
and produces foam cells. Oxidation of  LDL and 
its containing cholesterol have an important role in 
formation of  atherosclerotic plaques. The starting 
point of  this process is the damage caused by 
combination of  unsaturated lipids of  plasma or 
arterial membrane with oxygen or side products 
of  their oxidation. Macrophages have receptors for 
LDL, however proxified LDL can be identified by 
another receptor called acetyl LDL or collecting 
LDL. These receptors attract them more strongly 
in the way that cholesterol accumulates in 
macrophages to form foam cells. Reactions which 
cause LDL change are associated with changes in 
amino acids on protein part of  LDL.[3]
Low density lipoprotein is composed of  an 
ester cholesterol core surrounded by lipophilic 
antioxidants and phospholipids. Lipophilic 
antioxidants initially preserve LDL particle against 
deformation, however after antioxidants lowering, 
unsaturated fatty acids will be oxidized. In this 
step of  oxidation that is associated with small 
amount of  oxidized lipid products and unchanged 
ApoB‑100 protein, LDL particle undergoes some 
slight changes.
If  these steps continue and lipid oxidation 
products accumulate largely in LDL particle, 
these materials start reacting with amino acids of  
ApoB‑100 protein and change them by covalent 
bond formation, which results in LDL’s negative 
charge increase and degradation of  their protein 
part. Oxidative changes in ApoB‑100 contribute to 
the loss of  the ligand binding to the receptor that 
shows the inability of  Ox‑LDL to attach to the LDL 
receptor. The result is creating new binding sites to 
the collecting receptor. LDL oxidation is a process 
with free radicals in which unsaturated lipids 
convert to lipid peroxides by lipid peroxidation 
and then change to aldehyde products such as 
malondialdehyde (MDA), hexanone and other 
compounds. The produced aldehydes bond with 
amino groups of  ApoB‑100.
Malondialdehyde‑LDL is attracted to monocyte 
derived macrophages and produce foam cells. This 
is one of  the compounds that will be formed during 
lipid peroxidation. Ox‑LDL affects NO release and 
vascular smooth muscles. One of  the side‑effects 
of  Ox‑LDL formation is vascular contraction.[3]
Meanwhile, lipid peroxides accelerate plaque 
formation by inhibiting prostacyclin synthesis 
as a strong inhibitor of  platelets aggregation. 
Oxidation also converts phosphatidylcholine to 
lysophosphatidylcholine and produces sterols from 
cholesterol esters in lipid core of  LDL.
Therefore, oxidative changes of  LDL change 
lipid and protein components of  LDL. Ox‑LDL 
has many effects such as monocytes chemotaxis, 
inhibition of  macrophages movement, fat cells 
formation, more expression of  endothelial adhesion 
molecules, growth factor stimulation, chemokine 
expression, monocytes proliferation, fatty streaks 
formation, and thickening of  intima that is effective 
in the initial progress of  atherosclerosis.[36]
Malondialdehyde is the final product in lipid 
(especially LDL) peroxidations. This compound 
is an active aldehyde as well as an active type 
of  electrophiles, which can cause toxic stress in 
cells and advanced glycation end‑products. This 
aldehyde’s product is a biomarker for measuring 
stress oxidative level. During LDL oxidation most 
of  MDA is composed of  linoleic, arachidonic and 
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docosahexaenoic acids. In physiological pH, free 
MDA is anionic type and is able to react with NH
2
 
groups of  amino acids and proteins.[37]
Hypertension
Hypertension is a risk factor in cardiovascular 
diseases and stroke. These complications are 
generally caused by high diastolic blood pressure. 
Hypertension damages endothelium by increasing 
the hemodynamic pressure on endothelium and 
may increase the permeability of  arterial walls for 
lipoproteins. Elevated angiotensin II concentration 
stimulates SMC growth, increases inflammation 
and finally accelerates LDL oxidation in such 
patients.[38,39]
Hypertension is correlated with the increased 
risk of  myocardial infarction. Although, the 
complications of  hypertension were formerly 
attributed to diastolic blood pressure, there is much 
evidence showing that systolic blood pressure 
plays a role as well. The mechanism with which 
hypertension can accelerate atherosclerosis is still 
unknown; however, in animals fed with high fat, 
hypertension accumulates the fatty substances 
inside the arterial walls.[38,40‑43]
Defect in nitric oxide production or function
Nitric oxide is produced from the conversion 
of  L‑arginine to L‑citruline by enzymatic activity 
of  NADH related to nitric oxide synthase (NOS). 
This process needs flavin mononucleotid, flavin 
adenine dinucleotide, Ca+2/calmodolin, and 
tetrahydrobiopterin (BH
4
) as cofactors.[44] NO is 
produced in the vessels by isoform nitric oxide 
endothelial synthase (eNOS) after stress and 
stimulation by agonists such as bradykinin and 
acetylcholine. NO has different functions, but the 
most important one is its “endothelium derived 
vasodilating function for homeostasis.”[45,46]
There is endothelium related vasodilation in 
atherosclerotic vessels even before changes in the 
vascular structure, which shows decreased eNOS. 
It has been demonstrated that in special pathologic 
conditions such as severe hypercholesterolemia, 
malfunctioned eNOS, and peroxynitrite are 
produced instead of  NO.[45,46]
Dysfunction of  eNOS causes vascular 
dysfunctions such as atherosclerosis. All the 
effective risk factors of  atherosclerosis such as 
hyperlipidemia, diabetes mellitus, hypertension, 
and cigarette smoking are related to the damaged 
endothelium. Although, the effective mechanisms 
on endothelium are multifactorial, the most 
important one is the dysfunction of  eNOS/NO 
pathway, which include the decrease in activity and 
expression of  eNOS, decrease in NO sensitivity 
and increase in NO destruction by reaction to 
superoxide.[45,46]
Because of  eNOS expression in the vessel 
walls, the level of  eNOS decreases in advanced 
atherosclerosis which is probably because of  
reduced translation or increased mRNA‑instability 
of  eNOS.[47,48] Enzymatic activity of  eNOS can 
be inhibited by different mechanisms which are 
related to atherosclerosis and hyperlipidemia. 
Proatherogenic lipids such as Ox‑LDL and 
lysophosphatidylcholine prevent signal conduction 
from the activated receptor to eNOS.[45‑49]
There are reports about endothelium 
regeneration by antioxidants and superoxide 
dismutase, which shows the importance of  
superoxide in the damaged endothelium. 
Antioxidants can heal the damaged endothelium 
in human and animal models of  atherosclerosis.[50] 
Vitamin	C	is	particularly	effective	in	regeneration	
of  endothelium damaged by the most risk factors 
of  atherosclerosis.[51]
There are some evidence suggesting that eNOS 
is an anti‑atherogenic factor.[52] Endothelial and 
leukocyte adhesion, vascular SMC migration, 
and platelets aggregation, which are all important 
atherogenic stages, can be inhibited by NO and 
eNOS inhibition leads to the development of  
atherosclerosis. Furthermore, chronic consumption 
of  L‑Arginine (eNOS substrate) can prevent 
atherosclerosis in animals.[53]
Nitric oxide is produced in the endothelium and 
rapidly leaks to reach to the molecular targets in 
the vascular walls and vascular channels. It can 
react with transcription factors such as protein (I) 
activator and KB nuclear factor.[54] NO activates 
guanylate cyclase in vascular SMC and leads 
to increased cyclic guanosine monophosphate 
(cGMP), activation of  cGMP mediated 
protein kinase G, and vasodilation.[55] NO has 
anti‑atherogenic effects in addition to vascular 
tone adjustment capability.[46] NO has antiplatelet 
effects and inhibits adhesion and migration of  
platelets. It also inhibits the expression of  inducing 
thrombin of  platelet activating factor.[56]
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Nitric oxide has also anti‑proliferating effect, 
and can potentially inhibit the proliferation, 
migration, and extracellular matrix synthesis. 
It has anti‑inflammatory effects, too.[57]
Nitric oxide prevents translocation of  KB factor, 
blocks the cytokine stimulated expression of  
endothelial adhesion molecules and decreases 
neutrophils and monocytes activity[58] [Figure 4].
Inflammation
Numerous markers such as cytokines 
(TNF‑α, IL‑6 and‑18), CRP, adhesion molecules 
(Intercellular Adhesion Molecule‑1) are increased 
in plasma, following chronic inflammation.[59] 
Matrix metalloproteinase (MMP‑9 or gelatinase B) 
is secreted by macrophages and other inflammatory 
cells and is identified in various pathological 
processes such as tumor metastasis, general 
inflammation, respiratory diseases, vascular 
aneurysms, myocardial injury, or remodeling. It is 
also elevated in patients with unstable angina.[60] 
Independent of  IL‑18, there is a strong association 
between baseline MMP‑9 levels and future risk of  
cardiovascular death.[61‑63] The presence of  IL‑18 
and MMP‑9 identifies patients at very high risk.
Pro‑inflammatory cytokines derived from 
monocytes, macrophages and/or adipose tissues 
trigger CRP in the liver. CRP, a marker for 
acute‑phase of  inflammation, predicts early and 
late mortality in patients with acute coronary 
syndromes. CRP itself  promotes inflammation[62‑64] 
and atherogenesis through effects on monocytes 
and endothelial cells and increases the activity 
and concentration of  plasminogen activator 
inhibitor‑1 (PAI‑1).[61‑64] CRP is a marker for 
cardiovascular diseases; however, whether or not it 
should be used in routine screening is still a matter 
of  debate.[61‑64]
There is some evidence showing that 
inflammatory markers are also related to coronary 
artery disease. For example, CRP shows more 
predictive information than what other documented 
risk factors (such as cholesterol) do. Increased levels 
of  acute‑phase reactants such as fibrinogen and 
CRP can reflect the extravascular inflammation, 
which can intensify the atherosclerosis and its 
complications. Nevertheless, both factors are 
effective in increasing the inflammatory markers 
in patients prone to coronary artery disease.[3]
C‑reactive protein is a member of  pentraxin 
proteins family. It is an acute‑phase reactant, 
which releases after infection, acute injury, or 
other inflammatory stimulations.[65‑67] CRP levels 
increase during the inflammation, because of  the 
increase in plasma IL‑6 concentration, which is 
predominantly produced by macrophages[65‑67] and 
adipocytes.[67]
C‑reactive protein can be bound with 
micro‑organism “phosphocholine.” In this process, 
complement system can be bound with damaged 
foreign cells and reinforce the phagocytosis by 
macrophages which expresses a receptor for CRP.[65‑67] 
Recent studies show that patients with high baseline 
CRP levels are more prone to diabetes mellitus,[68] 
hypertension,[69] and cardiovascular diseases.[70] 
Cells which have a role in forming atherosclerotic 
plaques (monocytes, SMC, and T) stimulate production 
of  IL‑6, complement factors (C19‑C3‑C5‑C9), 
cytokines, CRP, and NO.[70‑72]
C‑reactive protein is a plasma protein which is 
very similar in both vertebrates and invertebrates.[73] 
Most of  it is produced in liver and is regulated by 
IL‑6.[45] A little amount of  CRP is also produced 
locally on blood lymphocytes.[74] Inflammatory 
mechanisms have a pivotal role in all steps of  
atherosclerosis. CRP may have a role in any of  
these steps through effective direct processes such as 
complement system activation, absorption, activity, 
and cellular modulation, lipid accumulation 
and thrombosis.[45] CRP directly affects arterial 
endothelial cells by reducing the expression of  
inhibitory complement factors on the endothelial 
cells.[75]
Thrombosis is also effective for developing 
atherosclerotic damage and accelerating the 
Figure 4: Roles of nitric oxide endothelial synthase in 
atherosclerosis
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cardiovascular events. Direct activities of  CRP 
for conducting the pro‑thrombotic stage include; 
reinforcement of  precoagulative activity[76] or 
reduction of  fibrinolysis.[77]
C‑reactive protein induces platelets binding to 
endothelial cells[78] and stimulates monocytes and 
lymphocytes absorption into endothelial walls. 
CRP intermediates the proliferation and activities 
of  vascular SMC, which leads to accumulation of  
these cells in the vascular intima that is a key factor 
in advancing vascular wall damage.
C‑reactive protein is a factor related to 
lipoprotein deposition and complement system 
activity in atherosclerotic plaques. It amplifies the 
activity of  compliment system, which particularly 
in the first steps of  atherosclerosis may lead to 
development and advancement of  atherosclerotic 
damage.[79]
Immune and infection mediated atherosclerosis
Mediators of  acquired and innate immunity 
are involved in atherosclerosis, as might be 
anticipated for a chronic inflammatory process.[80] 
In the chronic state, atheromata contain activated 
macrophages, T lymphocytes and mast cells, which 
are also present in inflammatory infiltrates. Innate 
immune reactions against viruses and bacteria 
have been included in the list of  pathogenic factors 
in atherosclerosis.[81]
Acute respiratory infection might be a risk factor 
for myocardial infarction. An increase in acute 
coronary diseases during winter infections and flu 
epidemics has been related to seasonal variations 
in	factor	VIIa	and	fibrinogen,	probably	induced	via	
activation of  the acute‑phase response.[82] In these 
circumstances, an immune response may support 
an inflammatory process and can be associated 
with increased trafficking of  macrophages into the 
artery wall causing increase in the incidence of  
atherosclerosis.[83]
The humoral immune response might be a 
risk factor for coronary heart disease, inducing 
inflammation that links immunity with coronary 
disease.
Immune reaction and infection cause endothelial 
dysfuction, cell injury and a pro‑inflammatory 
environment.[84] Endotoxins secreted by bacteria are 
considered as potent activators of various inflammatory 
reactions, stimulating circulating monocytes, and 
causing production of several cytokines.[85]
IL‑18 gene expression is stimulated by 
lipopolysaccharides and pro‑inflammatory 
cytokines. Infection is also a trigger of  IL‑18.
There is a relationship between the patho‑
physiology of  ischemic heart disease and infection as 
well as the severity of  atherosclerosis.[86] Chlamydia 
pneumoniae, Helicobacter pylori and cytomegalovirus 
are associated with atherosclerotic lesions.
Furthermore, viral and bacterial proteins can 
induce anti‑phospholipid antibody production 
in humans which might be an additional factor 
attacking endothelium.[87] C. pneumoniae should 
be more involved in coronary disease through 
different mechanisms. C. pneumoniae might be 
replicated and maintained in human macrophages 
and in endothelial cells. It might participate in the 
acute coronary process through a direct effect on 
atheroma and initiate the inflammatory process, 
subsequently being activated during inflammation 
and acutely exacerbating the response.
C. pneumoniae can colonize atheroma by plaque 
inflammation, contributing to plaque disruption. 
The controversial role of  C. pneumoniae in 
coronary events was also indicated by the effect 
of  antibiotic treatment. C. pneumoniae is sensitive 
to macrolides (clarithromycin, roxithromycin, 
and azithromycin),[88] but their anti‑infectious 
activity, an alternative mechanism for macrolides 
was suggested.[89] They may suppress macrophage 
activity which means that they may have 
anti‑inflammatory effects, different for each drug. 
Controversial results could be related to these 
different anti‑inflammatory effects.
Hemostatic factors
Currently,	fibrinogen	and	factor	VII	(homeostatic	
factors) are known as confounding risk factors in 
cardiovascular diseases.
There is a relationship between plasma 
fibrinogen level or PAI‑1 as a fibrinolysis inhibitor 
and the risk of  coronary artery diseases. Fibrinogen 
is a circulating glycoprotein which has activity in 
coagulation steps responding to tissue and vascular 
damage.[90]
In addition to thrombotic role, fibrinogen 
causes cellular proliferation,[91] contraction of  
damaged cellular walls, stimulation of  platelet 
aggregation,[92] and regulation of  cell adhesion.[93] 
Fibrinogen is an acute‑phase reactant similar to 
CRP and its synthesis can be increased in response 
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to inflammations or infections.[94] Epidemiologic 
information supports the correlation between 
fibrinogen levels and cardiovascular diseases, 
infarction, and ischemia. Fibrinogen participates 
in inflammation and thrombosis. Fibrinogen is 
probably less affected by inflammatory stimulation 
compared with CRP and consequently is a specific 
marker. Fibrinogen increase in patients with 
atherosclerosis can be a secondary phenomenon, 
although it participates in lesion formation and 
thrombosis.[95]
Factor	VII	 is	also	a	coagulative	protein,	which	
has an important role in thrombogenesis. Several 
studies demonstrate the correlation between factor 
VII	 and	 inflammatory	 factors	 such	 as	 IL‑6	 and	
CRP in patients with hypercholesterolemia, which 
shows their pathophysiologic correlation. There are 
also some reports showing the correlation between 
coagulation system constituents (fibrinogen and 
factor	VII)	or	fibrinolytic	factors	(tissue	plasminogen	
activator, PAI) and atherosclerosis[96] [Figure 5].
Furthermore, several plant with antioxidant 
activity have been shown to decrease the fibrinogen 
and	factor	VII	levels	even	more	than	statins.[97‑99]
Homocysteine
Although homocysteine does not seem to be a 
strong predictor of  athrosclerosis, Cavalca et al.[100] in 
their study have reported that plasma homocysteine 
level might be a cardiovascular disease indicator. 
Impaired homocysteine metabolism may 
result in oxidative stress,[101] which can play 
a role in hyperhomocysteinemia‑mediated 
vascular disorders.[102,103] Homocysteine increases 
TNF‑expression, which enhances oxidative stress 
and induces a pro‑inflammatory vascular state that 
might contribute to the development of  coronary 
atherosclerosis.[104]
Antioxidants and atherosclerosis: New hope 
for herbal therapy
Trace amounts of  antioxidants are able to protect 
cell membranes and other body compartments 
against oxidants.[105,106] The equilibrium establishment 
between per‑ and anti‑oxidants helps cells to regain 
their normal physiologic function.[107]
Antioxidants are able to prevent diseases such as 
Alzheimer,[108] seizure, cancer,[109,110] aging,[105] and 
atherosclerosis[111,112] by reducing the effects of  free 
radicals. Producing reactive oxygen species (ROS) 
in cells is a natural process. This production can be 
amplified in different pathophysiologic conditions 
such as inflammation, immunologic diseases, 
drug and alcohol metabolism, ultraviolet ray or 
radiotherapy, and antioxidant vitamins deficiency. 
Uncontrolled ROS release usually damages cellular 
macromolecules such as deoxyribonucleic acid, 
protein, and lipid.[113]
Antioxidants can function through these 
mechanisms:
•	 Reducing	reactive	oxygen	concentration
•	 Inhibiting	lipid	chain	oxidation	by	absorption	
of  free radicals
•	 Inhibiting	 free	 radicals	 production	 by	 metal	
ions chelating agents peroxide decomposition
4. Breaking the reaction chain to inhibit hydrogen 
absorption by activated radical.[114]
In vitro peroxidation is affected by activity of  
enzymes such as superoxide dismutase, catalase, 
and glutathione peroxidase. Ions such as Mn+2, 
Cu+2, Zn+2, Se+2, and Fe+2 act as cofactors of  
antioxidating enzymes. Since lipid peroxidation 
is considered as the key event in atherosclerosis, 
antioxidant protection is often related to 
preventing lipid peroxidation. Therefore, reduction 
of  lipoproteins oxidative change in the body by 
natural and synthetic antioxidants is an effective 
way to prevent cardiovascular disorders. Rapid 
advancements in understanding the molecular 
mechanisms of  atherosclerosis have led to discover 
and suggest mechanisms to postpone the progress 
of  coronary artery disease.[115]
Antioxidants such as vitamin E, selenium, 
beta‑carotene and chemical compounds such as 
butyl hydroxytoluene and butyl hydroxyanisol can 
Figure 5: Stages of fibrinolyse, anticoagulation, and platelet 
inhibition
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and increase the total amount of  antioxidants.[121,122] 
The effect of  such food supplements as a modulator 
in ester proteins synthesis has been approved.
Medicinal herbs, as a source of  different 
antioxidants, can be very effective in modulating 
oxidative stress derived cardiovascular or renal 
damages.[123,124] Although different components of  
plants can have antioxidant effect, the main part 
of  such effects is attributed to phenol compounds.
Flavonoids are a group of  phenolic compounds 
with low molecular weights. Their basic structure 
is similar and found in fruits and vegetables. The 
amount and type of  flavonoids in different plants 
depend on the species, growth, and maturity of  
the plants. More than 8000 phenolic structures are 
known which are composed of  various molecules 
prevent cell membrane oxidation.[116,117] However, 
their widespread use has been limited because 
of  their toxic effect. Therefore, studies on some 
natural compounds with antioxidant properties 
without toxic effects to inhibit lipid peroxidation 
and consequently to prevent related diseases seem 
necessary.
Herbal compounds such as some plants’ essence 
and flavonoid extracts mainly have antioxidant 
properties.[118,119] They also have less toxicity and 
side‑effects compared with uncontrolled amounts 
of  chemical compounds.[120]
Several studies have demonstrated that 
receiving a mixture of  specific antioxidants as food 
supplements decrease the production of  MDA and 
protein carbonyl, decrease erythrocyte hemolysis, 
Table 2: Important medicinal plants with antioxidant and hypolipidimic activities
Row Plant name Family Region Subject Reference
1 Verjuice* Vitis vinifera Iran Rabbit [130]
2 Cornelian cherry Cornaceae Black Sea region Rabbit [131]
3 Allium hirtifolium Amaryllidaceae Turkey to Tien Shan Rabbit [132]
4 Kelussia odoratissima Mozaffarian Umbelliferae Iran Mice [133]
5 Hypericum perforatum Hypericaceae Europe, Turkey Rat [134]
6 Capparis dedicua Capparidaceae India, Pakistan Rat [135,136]
7 Aconitum heterophyllum Rununculaceae Mountainous parts of the 
Northern hemisphere
Rat [137]
8 Dalbergia latifolia Fabaceae India Rat [138]
9 Aloe vera gel Xanthorrhoeaceace Northern Africa Mouse [139]
10 Hibiscus cannabinus L Malvaceae India and Western world Rat [140]
11 Eclipta prostrata Asteraceae India, China Rat [141]
12 Moringa oleifera Lam Moringaceae Northwestern India Rat [142]
13 Terminalia chebula Combretaceae Southern Asia Rat [143,144]
14 Pithecellobium Dulce Leguminosae Tropical regions, America Rat [145]
15 Ougeinia Oojeinensis Fabaceae India Rat [146]
16 Randia dumetorum and 
Paederia foetida
Rubiaceae and 
Paederia foetida
Tropical regions, Asia Rat [147]
17 Sesbania grandiflora Fabaceae India, Malaysia Rat [148]
18 Luffa aegyptiaca Cucurbitaceae Rabbit [149]
19 Lycium barbarum Solanaceae China Rabbit [150]
20 Tinospora cardifolia Menispermaceae India, Myanmar Rat [151,152]
21 Bauhinia purpurea Fabaceae South China Rat [153]
22 Piper longum Piperaceae Java, Indonesia Rat [154]
23 Urtica dioica Urticaceal Europe, Asia Rat [155]
24 Psidium guajava Linn Myrtaceae Tropical regions Rat [156]
25 Piliostigma thonningii Fabaceae Asia, America Rat [157]
26 Aloe vera leaf gel Xanthorrhoeaceace Northern Africa Rabbit [158]
27 Hypericum perforatum Hypericaceae India, and China Rabbit [159]
28 Allium hirtifolium Boisson Amaryllidaceae Asia, Turkey to Tien Shan Rabbit [97]
*Verjuice is a highly acidic juice made mostly from viniferacea family or by pressing unripe grapes, crab‑apples or other 
sour fruit
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such as phenolic acids to fully polymerized 
compounds such as tannins. They are classified in 
flavonoid main groups comprising anthocyanins, 
flavonols, flavones, neoflavones, isoflavones, and 
dihydroflavones.[125]
Flavonoids are among potent antioxidants, free 
radical scavengers, metal excreters, ROS‑family 
compounds collector, and lipid peroxidation 
inhibitors. Studies show that flavonoids inhibit 
LDL oxidation in macrophage culture media and 
also reduce Ox‑LDL absorption by macrophage 
sweeping receptors.[126,127]
Considering the therapeutic effect of  flavonoids 
for cardiovascular diseases, using plants with 
such	 effects	 seems	 necessary.	 Various	 studies	
with promising results have been done on plants 
with such properties.[128,129]
The most important medicinal herbs with 
documented antioxidant activity and hypolipidemic 
effects are as follows.[130‑135] Some of  the most 
important plants with antioxidant activities and 
hypolipidemic properties are listed in Table 2.
Rhus coriaria, Juglans regia, Carum carvi, Cornus 
mas, Ocimum basilioum, Apium graveolens, Silybum 
marianum, Artemisia dracunculus, Plantago psyllium, 
S. marianum, Carduus marianus, Anethum graveolens, 
Rheum ribes, Lepidium sativum, Boswellia carterii, 
J. regia, Trigonella foenum‑graecum, Allium sativum, 
Trifolium pretense, Artemisia sp., Pistaciam atlantica, 
Pisacia mutca, Nigella sative, Berberis vulgaris, Berberis 
thunbergii, Phoenix dactylifeva, Sesamum indicum, 
Olea europaea, Croucus stivus. Arachis hypogaea, 
Citrus limon, Linum usitatissimum, Aloe littoralis, Aloe 
vera, Ziziphus jujube, Zingiber officinale, Onopordon 
acanthium, Celosia cristata, Mukul comiphora.
CONCLUSIONS
Atherosclerosis starts with fatty streaks formation 
and progresses with atheroma and atherosclerotic 
plaque formation.[159‑161] Hypercholesterolemia, 
LDL increase, HDL decrease, lipid oxidation, 
hypertension, malproduction and dysfunction of  
NO, and inflammation are the most facilitating 
factors for atherosclerosis.
Lipid oxidation, in the form of  Ox‑LDL, 
demonstrates the first step of  atherosclerosis. MDA 
shows lipid peroxidation level and is a marker of  
increased oxidative stress. CRP is an indicative 
marker of  body’s response to inflammatory 
processes. It is one of  the most important 
pathogenesis factors along with fibrinogen in 
atherogenic processes. Nitric oxide is known as a 
vasodilator and endothelial survival factor which 
enhances the endothelial cell proliferation and 
migration. In special pathologic conditions such 
as severe hypercholesterolemia, peroxynitrate 
concentration increases, which leads to severe 
atherosclerotic damage. Considering the role of  
oxidative stress and lipid oxidation in formation 
and progress of  atherosclerosis and endothelial 
damage, using antioxidants, especially herbal types 
can be beneficial.
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